Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Operating Expenses: 2010-2025

Historic Operating Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $212.4 million.

  • Arrowhead Pharmaceuticals' Operating Expenses rose 30.93% to $212.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $731.1 million, marking a year-over-year increase of 20.92%. This contributed to the annual value of $731.1 million for FY2025, which is 20.92% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Operating Expenses stood at $212.4 million, which was up 9.85% from $193.3 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Operating Expenses ranged from a high of $212.4 million in Q3 2025 and a low of $61.0 million during Q1 2021.
  • Moreover, its 3-year median value for Operating Expenses was $161.5 million (2025), whereas its average is $152.4 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Operating Expenses surged by 100.10% in 2021 and then dropped by 11.02% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Operating Expenses (Quarterly) stood at $90.8 million in 2021, then grew by 15.34% to $104.7 million in 2022, then spiked by 33.83% to $140.1 million in 2023, then increased by 17.00% to $163.9 million in 2024, then surged by 30.93% to $212.4 million in 2025.
  • Its Operating Expenses was $212.4 million in Q3 2025, compared to $193.3 million in Q2 2025 and $161.5 million in Q1 2025.